CD119 antibody targets the CD119 antigen, also known as the interferon gamma receptor 1 (IFNGR1), a critical component of the immune system. IFNGR1 is a cell surface receptor that binds to interferon-gamma (IFN-γ), a cytokine pivotal in mediating innate and adaptive immunity. Structurally, it is a transmembrane protein that forms a heterodimeric complex with IFNGR2 to activate downstream signaling via the JAK-STAT pathway, triggering antimicrobial, antiviral, and antitumor responses.
CD119 is expressed on immune cells (e.g., macrophages, T cells) and non-immune cells, playing roles in pathogen clearance, antigen presentation, and inflammation regulation. Mutations in the IFNGR1 gene are linked to Mendelian Susceptibility to Mycobacterial Diseases (MSMD), a rare immunodeficiency disorder characterized by severe infections with weakly virulent mycobacteria.
CD119 antibodies are widely used in research to study IFN-γ signaling, immune cell activation, and disease mechanisms. They are also employed in diagnostics (e.g., flow cytometry, immunohistochemistry) to quantify receptor expression in immune disorders or cancers. Therapeutic applications are emerging, with some antibodies explored as antagonists to modulate hyperinflammatory responses or as agonists to enhance IFN-γ pathway activity in immunodeficiencies. Their specificity makes them valuable tools for dissecting IFN-γ-related pathologies and developing targeted therapies.